Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University: Carcinoma trials

The registry lists 37 Carcinoma studies with Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University as lead sponsor. 24 are open to participants now and 1 have results posted.

Phase 1 1Phase 2 18Phase 3 2Phase 4 1No phase 17(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Reconstruction of Cervical Lymphatic System During Head and Neck Squamous Cell Carcinoma SurgeryNot yet recruitingNCT06815705Not applicable
• Effect of Prehabilitation During the Conversion Therapy on Postoperative Outcomes in Unresectable Hepatocellular CarcinomaNot yet recruitingNCT06749678Not applicable
• The Value of CEUS in Assessing the Response of Cervical Lymph Nodes After NACI for HNSCCRecruitingNCT06727162
• Ultrasound-Guided Microwave Ablation Vs. Surgery for Low-Risk PapilaryThyroid CarcinomaRecruitingNCT06725576
• mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan CriteriaRecruitingNCT06607107Phase 2
• Single-Incision Gasless Endoscopic Total Thyroidectomy Via Subclavian Approach Versus Open Surgery for PTCRecruitingNCT06592755
• Postoperative Adjuvant Therapy of Donafenib for Hepatocellular CarcinomaRecruitingNCT06581315Not applicable
• Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Cognitive Function in Patients With Resectable Head and Neck Squamous Cell CarcinomaRecruitingNCT06576180
• Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell CarcinomaRecruitingNCT06575322
• Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid TumorNot yet recruitingNCT06551896Phase 2
• Deep Learning-based sbORN Diagnostic ModelRecruitingNCT06463392
• Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCCNot yet recruitingNCT06366945Phase 2
• Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell CarcinomaRecruitingNCT06323369Phase 2
• AI-Based Multimodal Multi-tasks Analysis Reveals Tumor Molecular Heterogeneity, Predicts Preoperative Lymph Node Metastasis and Prognosis in Papillary Thyroid CarcinomaRecruitingNCT06241092
• Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and NeckNot yet recruitingNCT06016413Phase 2
• Using Vitamin D to Reduce Oral Mucosal Inflammation in Chemotherapy Patients With Oral Squamous Cell CarcinomaRecruitingNCT06016400Phase 2/3
• Temporal Diffusion Spectroscopy MRI in Predicting the CPS of PD-L1 Expression and the Efficacy of Neoadjuvant TherapyRecruitingNCT05964595
• Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCCRecruitingNCT05941338Phase 2
• Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular CarcinomaRecruitingNCT05924997Phase 1/2
• Utidelone Treated for the Recurrent or Metastatic Urothelial CarcinomaRecruitingNCT05895864Phase 2
• Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)RecruitingNCT05582265Phase 3
• Peritumoral Microbubbles and CEUS for SLN Detection and Biopsy in HNSCCRecruitingNCT05437380Not applicable
• Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)RecruitingNCT05098119Phase 2
• A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCCRecruitingNCT04992559Phase 2
• Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal CarcinomaCompletedNCT01621880Phase 2Results posted
• Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft RejectionStatus unknownNCT05913583
• Study to Assess the Feasibility in Bile cfDNA of Resectable Biliary Tract CarcinomasStatus unknownNCT05783973
• Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)Active, not recruitingNCT05724329Phase 2
• HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCCStatus unknownNCT05493332Phase 2
• A Prospective, Randomized, Controlled Clinical Study of BET Combined With Tympanostomy Tube Insertion in the Treatment of Intractable OME After Radiotherapy for NPCStatus unknownNCT05449184Not applicable
• A Prospective, Single-arm Clinical Study of Pabrolizumab in Combination With Cisplatin + 5-FU for the Neoadjuvant Treatment of Unresectable, Advanced Squamous Carcinoma of the Temporal Bone Single-arm Clinical StudyStatus unknownNCT05444673Phase 4
• A Nomogram Model to Predict Central Lymphnode Metastasis in Thyroid Papillary CarcinomaCompletedNCT05191927
• Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After SurgeryCompletedNCT04962958Phase 2
• Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell CarcinomaActive, not recruitingNCT04718415Phase 2
• Neoadjuvant Chemotherapy or Chemoradiotherapy in Resectable Oesophageal Carcinoma（NewEC Study）CompletedNCT04027543
• Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid StenosisSuspendedNCT02022293Phase 2
• Effect of Edaravone on Radiation-induced Temporal Lobe NecrosisCompletedNCT01865201Phase 2